In solid tumors, neoadjuvant or adjuvant immune checkpoint blockade increases treatment-related grade 3 or 4 adverse

Luca Bertolaccini1

  • 1IEO, European Institute of Oncology IRCCS, Milan, Italy (L.B.).

PubMed
Abstract

Related Concept Videos